HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops
17. Mai 2021 09:00 ET | Harrow Health, Inc.
NASHVILLE, Tenn., May 17, 2021 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of...
HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal
03. Dezember 2020 07:30 ET | Harrow Health, Inc.
NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the American...
HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference
20. November 2020 07:30 ET | Harrow Health, Inc.
NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial...
HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
Harrow Health Publishes Third Quarter 2020 Letter to Stockholders
09. November 2020 16:01 ET | Harrow Health, Inc.
NASHVILLE, Tenn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health’s Letter to...
HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
Harrow Health Appoints Larry Van Horn to its Board of Directors
30. September 2020 08:00 ET | Harrow Health, Inc.
NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors. Mark L. Baum, CEO of Harrow...
HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
Leading Peer-Reviewed Journal Publishes Clinical Study on ImprimisRx’s Combination Prescription Eyedrops
13. Juli 2020 07:30 ET | Harrow Health, Inc.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow...
HarrowHealth_LOGO_SHAPE_COLOR_WHITE_HOR-02.jpg
ImprimisRx’s Patented Klarity-C® 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometrists
18. Juni 2020 07:30 ET | Harrow Health, Inc.
SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow...
HarrowHealth Logo.jpg
ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services
24. März 2020 07:30 ET | Harrow Health, Inc.
NASHVILLE, Tenn., March 24, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding...
HarrowHealth Logo.jpg
ImprimisRx® Announces Supply Agreement with EyeCare Services Partners
12. März 2020 07:30 ET | Harrow Health, Inc.
SAN DIEGO, March 12, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of...
HarrowHealth Logo.jpg
ImprimisRx® Announces Supply Agreement with iOR Partners
09. März 2020 07:30 ET | Harrow Health, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of...